These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503 [TBL] [Abstract][Full Text] [Related]
5. B and T cell prolymphocytic leukaemia. Cross M; Dearden C Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622 [TBL] [Abstract][Full Text] [Related]
6. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment. Collignon A; Wanquet A; Maitre E; Cornet E; Troussard X; Aurran-Schleinitz T Curr Oncol Rep; 2017 Apr; 19(4):29. PubMed ID: 28324286 [TBL] [Abstract][Full Text] [Related]
7. Management of prolymphocytic leukemia. Dearden C Hematology Am Soc Hematol Educ Program; 2015; 2015():361-7. PubMed ID: 26637744 [TBL] [Abstract][Full Text] [Related]
9. Current treatment options in prolymphocytic leukemia. Robak T; Robak P Med Sci Monit; 2007 Apr; 13(4):RA69-80. PubMed ID: 17392661 [TBL] [Abstract][Full Text] [Related]
10. Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy. Szuszies CJ; Hasenkamp J; Jung W; Koch R; Trümper L; Wulf GG Int J Hematol; 2014 Nov; 100(5):425-8. PubMed ID: 25258193 [TBL] [Abstract][Full Text] [Related]
11. Complete response to alemtuzumab in a patient with B prolymphocytic leukemia. Chaar BT; Petruska PJ Am J Hematol; 2007 May; 82(5):417. PubMed ID: 17160995 [No Abstract] [Full Text] [Related]
12. Alemtuzumab in peripheral T-cell malignancies. Dearden C Cancer Biother Radiopharm; 2004 Aug; 19(4):391-8. PubMed ID: 15453953 [TBL] [Abstract][Full Text] [Related]
14. T-cell prolymphocytic leukemia. Dearden CE Med Oncol; 2006; 23(1):17-22. PubMed ID: 16645226 [TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. McCune SL; Gockerman JP; Moore JO; Decastro CM; Bass AJ; Chao NJ; Long GD; Vredenburgh JJ; Gasparetto C; Adams D; Payne N; Rizzieri DA Leuk Lymphoma; 2002 May; 43(5):1007-11. PubMed ID: 12148879 [TBL] [Abstract][Full Text] [Related]
16. TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy. Hu Z; Li S; Medeiros LJ; Sun T Hum Pathol; 2017 Jul; 65():175-179. PubMed ID: 28232160 [TBL] [Abstract][Full Text] [Related]
17. Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia. Shumilov E; Hasenkamp J; Szuszies CJ; Koch R; Wulf GG Acta Haematol; 2021; 144(1):105-110. PubMed ID: 32259827 [TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Robak T Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704 [TBL] [Abstract][Full Text] [Related]
19. [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab]. Fløisand Y; Brinch L; Gedde-Dahl T; Tjønnfjord GE Tidsskr Nor Laegeforen; 2004 Mar; 124(6):768-70. PubMed ID: 15039804 [TBL] [Abstract][Full Text] [Related]